IVD China last week: Tellgen, Zoetis Diagnostic Lab and BioMérieux, DIAN Diagnostics, Berry Genomics

Tellgen Acquires Wuhan HealthCare Biotechnology for CNY 328 Million

Tellgen Life (300642.SZ) announced plans to acquire a total of 82% equity in Wuhan HealthCare Biotechnology Co., Ltd., further expanding its technology and product portfolio in molecular diagnostics. Upon completion, Wuhan HealthCare will become a controlling subsidiary and be consolidated into Tellgen’s financial statements. Specializing in molecular diagnostics for cancer and cardiovascular diseases, Wuhan HealthCare holds core technologies including fluorescence in situ hybridization (FISH) and PCR, with competitive advantages in tumor gene testing and companion diagnostics. As a leading domestic player in chemiluminescence and flow fluorescence technologies, Tellgen aims to complement its molecular diagnostics product line, create an integrated “immunology + molecular” diagnostic solution, accelerate commercialization through its hospital and third-party lab networks, and strengthen its position in high-growth areas such as cancer early screening and precision medicine.

Zoetis Diagnostic Lab and BioMérieux Enter Strategic Partnership

On August 7, Zoetis Diagnostic Laboratory and BioMérieux Diagnostics Products (Shanghai) Co., Ltd. reached a strategic cooperation agreement to establish a “Pet Clinical Microbiology Demonstration Laboratory.” The two parties will leverage their respective strengths to improve diagnostic capabilities in pet clinical microbiology, drive technological innovation, and upgrade service standards in the veterinary sector. 

“Through cross-disciplinary collaboration, the partnership aims to enhance the industry’s capacity to address complex health challenges and promote the One Health concept for humans, animals, and the environment.” represented by Mr. Li Gengpu, Senior Director of Marketing, Greater China

DIAN Diagnostics Launches “Gene Navigator” All-in-One Machine for Intelligent Bioinformatics Analysis

Gene data, a key resource in life sciences, plays a critical role in disease diagnosis, genetic screening, and treatment guidance. Bioinformatics analysis is essential for decoding these data, yet traditional workflows are often complex, lengthy, and highly specialized—particularly in phenotype association mining for genetic diseases and low-frequency variant interpretation in oncology. 

Addressing these challenges, DIAN Diagnostics has developed the “Gene Navigator” bioinformatics all-in-one machine, featuring dual intelligent engines—“Phenotype Compass” and “Variant Beacon”—and four supporting systems to deliver a full-stack, reliable, and easy-to-maintain intelligent analysis solution for healthcare institutions.

Berry Genomics Partners with Leading Expert to Launch Joint Venture for Newborn and Pediatric Genetic Disease Services

Preventing genetic diseases in newborns and children is key to reducing birth defects and improving population health. Berry Genomics (000710) will establish a joint venture in Zhengzhou, Henan, with Professor Li Wei from Beijing Children’s Hospital, aiming to provide integrated genetic disease detection services for newborns and children in Henan and other key regions. Leveraging the National Children’s Medical Center’s leadership in pediatric genetic disease screening and treatment, along with Berry Genomics’ technical expertise, the project will serve as a model for tertiary prevention of birth defects in China. Supported by the AI-powered GENOisi platform, the initiative will deliver both economic and social benefits, creating a replicable and scalable model for regional child health management.